Autoimmune diseases, immune modulation, inflammation, and self-tolerance
297 articles
Only 23% met major response criteria after stronger lupus treatment. Black patients had greater initial disease burden and lower observed response.
A placebo-controlled trial tested low-dose naltrexone for Crohn's disease, tracking inflammation, symptoms, and safety. Results are not supplied.
A Swedish study of 13,748 MS therapy episodes finds rituximab users developed IBD far more often than users of other modern MS drugs, mostly Crohn disease.
Two phase 3 trials found fewer MS relapses with remibrutinib than teriflunomide, but long-term disability benefits remain unclear.
Early evidence suggests deep B-cell depletion may enable drug-free remission in rheumatoid arthritis, but durability and safety remain uncertain.
Long-lived plasma cells may sustain autoimmune disease despite treatment. A review weighs emerging therapies against major evidence gaps.
Cellular senescence drives vascular inflammation in giant cell arteritis. Could senolytics like fisetin and quercetin reshape treatment?
Pooled data from 1,299 SLE patients show belimumab nearly halts organ damage accrual and slashes steroid use over 8 years.
A nanoscale chromatin-mapping platform uncovers how a single noncoding variant creates a rogue DNA motif that silences a key mTOR-regulating gene, raising autoimmunity risk.
A rigorous phase 2b trial finds low-dose IL-2 robustly expands regulatory T cells but does not slow beta-cell loss in newly diagnosed type 1 diabetes.
A comprehensive review maps how regulatory T cell dysfunction fuels autoimmune liver diseases and charts emerging therapeutic strategies to restore immune balance.
Immunosenescence may explain why uveitis becomes refractory with age — and points to new precision therapy strategies.
